1. Home
  2. IPO
75656
Off
Supriya Lifescience Ltd IPO

Supriya Lifescience Ltd IPO

  • Status: Closed
  • RHP:
  • ₹ 14,310 / 54 shares

    Minimum Investment

IPO Details

  • Open Date

    16 Dec 2021

  • Close Date

    20 Dec 2021

  • IPO Price Range

    ₹ 265 to ₹274

  • IPO Size

    ₹ 700 Cr

  • Listing Exchange

    NSE, BSE

  • Listing Date

    28 Dec 2021

With just a few clicks, Invest in IPO's!

+91
Resend OTP

By proceeding, you agree to all T&C*

hero_form
Timeline Subscription Status Objective Financials SWOT FAQ Contacts

IPO Timeline

Last Updated: 08 March 2022 12:11 PM by 5Paisa

The active pharmaceuticals manufacturer, Supriya Lifescience Ltd will open its issue for subscription between December 16 and December 20. The company will be listed on the stock exchange on December 28, 2021. The price band for the issue is Rs.265-274 per share with the minimum investment  being Rs.14,796 (54 shares * Rs.274). 
The issue consists of a fresh issue worth Rs.200 crore and an offer for sale worth Rs.500 crore by Satish Waman Wagh, making the total issue worth Rs.700 crore. The promoter holds a stake of 99.98% stake in the company. The book running lead managers to the issue are ICICI Securities Ltd and Axis Capital Ltd. 

Objectives of the issue:
1. Rs.85.38 crore from the net proceeds of the issue is to be used to fund capital expenditure requirements of the company
2. Rs.67 crore is to be used for the repayment and prepayment of debt availed by the company

Supriya Lifescience, founded in 1987, is one of the key manufacturers and suppliers of active pharmaceutical ingredients (APIs). The company offers 39 APIs which are focused on diverse therapeutic segments like antihistamine, vitamin, anesthetic, anti-asthmatic and anti-allergic. The company is the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride. These account for 45-55% and 65-70% of the exports of API exports of the country between FY17-FY20. In FY20, Supriya Lifescience was one of the largest exporters of Salbutamol Sulphate, in terms of volume. 

In FY21, the company exported its products to 78 countries, 1,060 customers, including 286 distributors. Supriya Lifescience has expanded their API business to Europe, Latin America and North America. Their customers include Syntec Do Brasil LTDA, American International Chemical Inc, AT Planejamento E Desenbolvimento De Negocios Ltda, Mankind Pharma Ltd etc. 

The company has a manufacturing facility in Maharashtra which is spread across 23,806 sq mts. They also operate 5 cleanrooms and are in the process of setting up 2 more new cleanrooms. These 7 are going to be commercialized in FY22. The manufacturing facility of Supriya Lifescience has received approvals from USFDA, EDQM TGA- Australia, KFDA- Korea, PMDA Japan, NMPA- China and Health Canada. 

Particulars

(In Rs cr)

FY21

Q3 ended 31 December, 2020

FY20

FY19

Revenue from operations

396.22

255.71

311.64

277.84

PAT

123.83

76.18

73.37

39.42

EPS (In Rs)

-

10.41

10.03

5.39

 

Particulars

(In Rs cr)

Q3 ended 31 December, 2020

FY20

FY19

Total Assets

196.16

336.40

253.05

Total Borrowings

58.43

82.21

89.83

Equity Share Capital

14.63

14.63

14.63

Asset turnover

2.73

3.33

3.41

Debt to Equity ratio

0.25

0.55

0.95

 

Key Ratios

Particulars

 

Q3 ended 31 December, 2020

FY20

FY19

FY18

Gross Margin

63.15%

55.56%

47.14%

36.36%

EBITDA %

42.87%

33.92%

25.45%

13.79%

Profit Margin

28.44%

22.74%

13.79%

3.94%

Current ratio

1.69

1.26

0.98

0.82


Strengths:

1. The company has a significant leadership in the niche and key products market. They are the largest exporters of Chlorpheniramine Maleate and Ketamine Hydrochloride
2. Supriya Lifescience Ltd uses a backward integration model. As of now, 11 of their products, which account for 63.25% of the revenue, are backward integrated
3. The company has an added advantage of a high geographical diversification as they are spread across 78 countries across the globe
4. Supriya Lifescience Ltd has a very experienced and skillful operational personnel as well as experienced senior management and promoters

Risks:

1. If the company does not develop new products in time or the already commercialized products are not very well received in the market, it will adversely affect the financials of the company 
2. A manufacturing or quality control problem will negatively affect the reputation of the company, thus decreasing the goodwill among the customers
3. A significant amount of revenue is derived from a few specific products and if the demand for these products decrease, this will materially affect the business of the company
4. Failure to achieve optimal capital utilization or a shutdown or disruption in production will adversely affect the operations of the business

Will You Apply for Supriya Lifescience Ltd IPO?

Yes No Maybe

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
footer_form

FAQs

The issue size is around Rs.700 crore.

The maximum is 13 lots- 702 shares, worth Rs.1,92,348. 

1 lot of Supriya Lifescience IPO has 54 shares. 

On December 28 th, 2021, Supriya Lifescience Ltd will be listed on the stock exchanges. 

NSE and BSE both. 

The price band set for each share of Supriya Lifescience Ltd, is Rs.265-Rs.274 per share. 

Link Intime India Pvt Ltd is the registrar to the Supriya Lifescience IPO. 

The pre issue shareholding will stand at 99.98%.

Way to check 1-  First you need to go to the registrar’s site- Link Intime India Pvt Ltd and then visit the IPO allotment page. From the drop down menu, select Supriya Lifescience Ltd. Then, enter your PAN card details and select the application type- ASBA or Non-ASBA and enter the required details. After this the status is displayed on the screen.
Way to check 2- Visit the BSE application website page, select equity and then select Supriya Lifescience Ltd from the drop down menu. After entering your PAN card details and application number, the status is displayed on the screen. 

The minimum investment required to apply for the Supriya Lifescience Ltd IPO is Rs.14,796. 
It is the upper range of the IPO price i.e. Rs.274*54 shares (1 lot).  Minimum investment in an IPO is the amount of money that you need to invest in order to receive 1 lot of shares of the IPO. The number of shares in 1 lot varies from IPO to IPO but normally, the minimum investment value is calculated by multiplying the number of shares in 1 lot with the upper price range of the IPO price per share.